Show simple item record

dc.creatorCeccarelli F., Perricone C., Cipriano E., Massaro L., Natalucci F., Capalbo G., Leccese I., Bogdanos D., Spinelli F.R., Alessandri C., Valesini G., Conti F.en
dc.date.accessioned2023-01-31T07:41:57Z
dc.date.available2023-01-31T07:41:57Z
dc.date.issued2017
dc.identifier10.1016/j.semarthrit.2017.03.022
dc.identifier.issn00490172
dc.identifier.urihttp://hdl.handle.net/11615/72329
dc.description.abstractObjective In the present review, the different phenotypes, clinimetric and imaging tools able to assess joint involvement in patients affected by Systemic Lupus Erythematosus (SLE) have been described and summarized. Furthermore, the current knowledge about the pathogenic mechanism and the potential biomarkers of this feature is reported. Methods A literature search was done in PubMed, accessed via the National Library of Medicine PubMed interface (http://www.ncbi.nlm.nih.gov/pubmed). Firstly, PubMed was searched using the term “systemic lupus erythematosus” OR “lupus” in combination with (AND) “joint” OR “articular”.Secondly, the same PubMed research was combined with other terms, such as “pathogenesis” OR “genetic” OR “antibodies” OR “biomarkers” OR “cytokines” OR “imaging” OR “ultrasonography” OR “magnetic resonance” OR “clinimetry”. Results After a stringent selection, we evaluated in the present review 13 papers concerning clinical phenotypes of SLE joint involvement, 14 concerning clinimetric assessment, 20 concerning imaging, and finally, 28 concerning pathogenesis and biomarkers. Further relevant data were obtained from the reference lists of articles returned using these search terms and from authors own experience and knowledge of the literature. Conclusion Despite the prevalence and severity of SLE joint involvement, more awareness and a deeper evaluation of the clinical heterogeneity of this manifestation are mandatory. Moreover, longitudinal studies are needed to assess the progression of this manifestation and to provide standard definitions and examination/recording protocols. © 2017 Elsevier Inc.en
dc.language.isoenen
dc.sourceSeminars in Arthritis and Rheumatismen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85018426278&doi=10.1016%2fj.semarthrit.2017.03.022&partnerID=40&md5=4d3981a91778ab971ed3d314588e13a9
dc.subjectbiological markeren
dc.subjectC reactive proteinen
dc.subjectinterferon regulatory factor 5en
dc.subjectinterleukin 1 receptor associated kinase 1en
dc.subjectSTAT1 proteinen
dc.subjecttumor necrosis factor receptor associated factor 6en
dc.subjectabatacepten
dc.subjectantirheumatic agenten
dc.subjectbiological markeren
dc.subjectbone erosionen
dc.subjectclinical featureen
dc.subjectDAS28en
dc.subjectdisease classificationen
dc.subjectdisease courseen
dc.subjecterythrocyte sedimentation rateen
dc.subjectfunctional assessmenten
dc.subjecthumanen
dc.subjectjoint limitationen
dc.subjectjoint radiographyen
dc.subjectmeta analysisen
dc.subjectmusculoskeletal disease assessmenten
dc.subjectnuclear magnetic resonance imagingen
dc.subjectpriority journalen
dc.subjectReviewen
dc.subjectrheumatoid arthritisen
dc.subjectsymptomatologyen
dc.subjectsystematic reviewen
dc.subjectsystemic lupus erythematosusen
dc.subjectultrasounden
dc.subjectarthritisen
dc.subjectcomplicationen
dc.subjectdiagnostic imagingen
dc.subjectdisease exacerbationen
dc.subjectjointen
dc.subjectpathologyen
dc.subjectpathophysiologyen
dc.subjectseverity of illness indexen
dc.subjectsystemic lupus erythematosusen
dc.subjectAbatacepten
dc.subjectAntirheumatic Agentsen
dc.subjectArthritisen
dc.subjectBiomarkersen
dc.subjectDisease Progressionen
dc.subjectHumansen
dc.subjectJointsen
dc.subjectLupus Erythematosus, Systemicen
dc.subjectSeverity of Illness Indexen
dc.subjectW.B. Saundersen
dc.titleJoint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessmenten
dc.typeotheren


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record